--- title: "Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 348 Shares of Stock" type: "News" locale: "en" url: "https://longbridge.com/en/news/279856408.md" description: "Guardant Health Director Musa Tariq sold 348 shares at $88.09 each, totaling $30,655.32, representing a 3.98% decrease in his ownership. Post-sale, he holds 8,394 shares valued at approximately $739,427.46. The transaction was disclosed to the SEC. Guardant Health's stock recently traded at $89.08, with a market cap of $11.68 billion. Analysts have mixed ratings, with a consensus average target price of $122.57, indicating a \"Moderate Buy\" rating. The company specializes in blood-based cancer diagnostics and reported a revenue increase of 39.4% year-over-year in its last earnings report." datetime: "2026-03-19T22:58:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279856408.md) - [en](https://longbridge.com/en/news/279856408.md) - [zh-HK](https://longbridge.com/zh-HK/news/279856408.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/279856408.md) | [繁體中文](https://longbridge.com/zh-HK/news/279856408.md) # Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 348 Shares of Stock Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Musa Tariq sold 348 shares of the firm's stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $88.09, for a total transaction of $30,655.32. Following the sale, the director owned 8,394 shares of the company's stock, valued at approximately $739,427.46. The trade was a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Get **Guardant Health** alerts: ## Guardant Health Trading Up 2.1% - 4 Healthcare Stocks With Massive Gains—and More to Come GH traded up $1.81 on Thursday, hitting $89.08. The company had a trading volume of 1,228,613 shares, compared to its average volume of 2,012,589. The company's fifty day moving average price is $102.70 and its 200 day moving average price is $90.31. Guardant Health, Inc. has a 1 year low of $36.36 and a 1 year high of $120.74. The firm has a market cap of $11.68 billion, a P/E ratio of -26.91 and a beta of 1.67. Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The firm had revenue of $281.27 million during the quarter, compared to analyst estimates of $269.74 million. During the same period in the prior year, the company posted ($0.62) EPS. The firm's revenue for the quarter was up 39.4% on a year-over-year basis. On average, analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year. ## Institutional Trading of Guardant Health - Deciphering Disruption: Inside Cathie Wood's Latest Plays A number of hedge funds have recently added to or reduced their stakes in GH. V Square Quantitative Management LLC acquired a new stake in shares of Guardant Health in the fourth quarter worth approximately $27,000. Chesapeake Asset Management LLC acquired a new position in Guardant Health during the fourth quarter worth approximately $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Guardant Health during the fourth quarter worth approximately $31,000. Elyxium Wealth LLC purchased a new position in Guardant Health during the fourth quarter worth approximately $35,000. Finally, Parallel Advisors LLC boosted its holdings in shares of Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company's stock valued at $36,000 after purchasing an additional 219 shares during the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds. ## Wall Street Analyst Weigh In Several research analysts have recently issued reports on GH shares. Weiss Ratings restated a "sell (d-)" rating on shares of Guardant Health in a report on Thursday, January 22nd. Canaccord Genuity Group upped their price objective on shares of Guardant Health from $125.00 to $135.00 and gave the company a "buy" rating in a research note on Friday, February 20th. UBS Group reissued a "buy" rating and issued a $175.00 target price on shares of Guardant Health in a report on Friday, January 30th. Leerink Partners lifted their target price on Guardant Health from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Friday, February 20th. Finally, Stifel Nicolaus raised their target price on Guardant Health from $120.00 to $130.00 and gave the company a "buy" rating in a report on Friday, February 20th. Twenty-one analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Guardant Health currently has an average rating of "Moderate Buy" and an average target price of $122.57. - 3 Fast-Growing Stocks Analysts See Doubling in Price **Read Our Latest Stock Analysis on Guardant Health** ## About Guardant Health (Get Free Report) Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide. The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes. ## Read More - Five stocks we like better than Guardant Health _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Guardant Health Right Now? Before you consider Guardant Health, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list. While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [Guardant Health, Inc. (GH.US)](https://longbridge.com/en/quote/GH.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [Direxion Daily S&P Biotech Bull 3X ETF (LABU.US)](https://longbridge.com/en/quote/LABU.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [iShares Genomics Immnlgy & Hlthcr ETF (IDNA.US)](https://longbridge.com/en/quote/IDNA.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) ## Related News & Research - [Caris Life Sciences, Inc. (NASDAQ:CAI) Receives Consensus Recommendation of "Hold" from Analysts](https://longbridge.com/en/news/281385092.md) - [Allworth Financial LP Reduces Holdings in Biodesix, Inc. $BDSX](https://longbridge.com/en/news/281318320.md) - [Tempus AI (TEM) Valuation Check After Daiichi Sankyo Oncology Collaboration Announcement](https://longbridge.com/en/news/281281204.md) - [Unichem Shareholders Clear Director Appointment and Key Related-Party Deals via Postal Ballot](https://longbridge.com/en/news/280959952.md) - [Guardant Health (GH) Valuation Check After TRICARE Coverage Win For Shield Blood Test](https://longbridge.com/en/news/272304771.md)